JP2022519619A - Bpa凍結乾燥製剤及び製造方法 - Google Patents
Bpa凍結乾燥製剤及び製造方法 Download PDFInfo
- Publication number
- JP2022519619A JP2022519619A JP2021545479A JP2021545479A JP2022519619A JP 2022519619 A JP2022519619 A JP 2022519619A JP 2021545479 A JP2021545479 A JP 2021545479A JP 2021545479 A JP2021545479 A JP 2021545479A JP 2022519619 A JP2022519619 A JP 2022519619A
- Authority
- JP
- Japan
- Prior art keywords
- bpa
- solution
- freeze
- preparation
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- 239000000243 solution Substances 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 58
- 230000008569 process Effects 0.000 claims abstract description 42
- 238000004108 freeze drying Methods 0.000 claims abstract description 19
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 14
- 238000012792 lyophilization process Methods 0.000 claims abstract description 13
- 239000003513 alkali Substances 0.000 claims abstract description 11
- 238000007710 freezing Methods 0.000 claims abstract description 11
- 230000008014 freezing Effects 0.000 claims abstract description 11
- 239000002253 acid Substances 0.000 claims abstract description 8
- 239000007864 aqueous solution Substances 0.000 claims abstract description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 238000001291 vacuum drying Methods 0.000 claims description 13
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 238000005092 sublimation method Methods 0.000 claims description 9
- 229930091371 Fructose Natural products 0.000 claims description 5
- 239000005715 Fructose Substances 0.000 claims description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 2
- 239000012931 lyophilized formulation Substances 0.000 claims description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 2
- 239000000347 magnesium hydroxide Substances 0.000 claims description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 239000012535 impurity Substances 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 2
- NFIVJOSXJDORSP-QMMMGPOBSA-N (2s)-2-amino-3-(4-boronophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(B(O)O)C=C1 NFIVJOSXJDORSP-QMMMGPOBSA-N 0.000 description 41
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 4
- 229910052796 boron Inorganic materials 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- -1 hydrosulphate Chemical compound 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000013386 optimize process Methods 0.000 description 2
- 238000012858 packaging process Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- NIFHFRBCEUSGEE-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O NIFHFRBCEUSGEE-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
- A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
であり、式中、Bは10B及び11Bを含む。Bが10Bである場合、薬物としてホウ素中性子捕捉療法(BNCT)に用いることができ、2種の異性体を有し、それぞれL型
である。2種の構造は、いずれも本発明の保護範囲内に含まれるべきであり、本発明に係るBPAは、好ましくはL型BPA(L-BPA)である。
BPA凍結乾燥製剤の製造方法
1.凍結乾燥過程において、最適化されたプロセスパラメータを用いることにより、凍結乾燥過程における水分の除去が不十分であること、温度の制御不良が生じることによる製品形態に対する悪影響を大幅に回避し、製品の水分を最低レベルに制御し、同時に温度が均一に伝達され、製品が軟らかくて膨らみ、粒子が均一であり、崩壊し、気泡が立ち、ばらばらになり、縮むなどの現象が発生しない。
2.製品は、再溶解性が高く、水を添加すると迅速に溶解し、純度が高く、安定性が高い。
3.製品に可視異物がなく、関連物質の含有量が低く、不純物制御効果が高い。
(1)予備凍結過程において、サンプルを-20℃~-60℃に降温させ、5-15時間維持することにより、サンプルを完全に凍結させる。
(2)昇華過程において、-15℃~-35℃に昇温させ、10-11paの真空を維持し、30-55時間維持する。
(3)真空乾燥過程において、セパレータを加熱し、0℃~40℃に昇温させ、4-10時間維持し、真空乾燥過程全体において10-11paの真空を維持する。
溶液調製タンクに注射用水を添加し、処方量のBPA及び補助材料を添加し、水酸化ナトリウム溶液を添加し、補助材料及び水酸化ナトリウム溶液を入れる容器をそれぞれ注射用水で洗浄して溶液調製タンクに移す。溶液が清澄になるまで撹拌する。pHを調整し、残りの注射用水を添加し、均一に撹拌し、中間体を検出し、濾過する。前記補助材料は、本発明に係る多価アルコールである。
中間体の含有量に基づいて充填量を調整し、充填し、半打栓し、凍結乾燥機に入れる。
予備凍結段階、昇華段階及び真空乾燥段階を含む。
取り出し:半製品から、クラス100層流の保護下で、栓なし、栓変位、瓶破裂などの不良品を取り出し、廃棄処理する。キャッピング:製造前、中、後にサンプリングしてその外観を検出する。
ラベリングし、パッケージに詰め、箱に詰め、入庫する。
Claims (15)
- 溶液調製過程及び凍結乾燥過程を含み、
溶液調製過程は、
(1)アルカリによりBPAと多価アルコールを水溶液に溶解して清澄溶液を得るステップと、
(2)酸により前記清澄溶液を7.5<pH≦8.5になるように調整して、BPA溶液を得るステップと、
を含み、
凍結乾燥過程は、
(3)前記BPA溶液を分注し、真空度10~20Paの条件で凍結乾燥して、凍結乾燥製剤を得るステップ
を含む、
BPA凍結乾燥製剤の製造方法。 - 前記溶液調製過程における、いずれかの前記「溶液」の温度が60℃以下であるように制御する、
請求項1に記載の方法。 - 前記BPAと多価アルコールとの重量部比は1:1~1.3である、
請求項1に記載の方法。 - 前記アルカリは、水酸化リチウム、水酸化ナトリウム、水酸化カリウム、水酸化カルシウム、水酸化マグネシウムを含む、
請求項1に記載の方法。 - 前記溶液調製過程において、アルカリによりBPAと多価アルコールを水溶液に溶解して、pH値が8.5~9.5である清澄溶液を得る、
請求項1に記載の方法。 - 前記多価アルコールは、フルクトース、ラクトース、ソルビトール、マルトース、マンニトール、キシリトール、リボース、グルコース、スクロースを含む、
請求項1、3及び5のいずれか一項に記載の方法。 - 前記溶液調製過程の後及び凍結乾燥過程の前に濾過ステップをさらに含む、
請求項1に記載の方法。 - 前記凍結乾燥過程の時間は39-80時間である、
請求項1に記載の方法。 - 前記凍結乾燥の真空度は10~11Paである、
請求項1に記載の方法。 - 前記凍結乾燥過程は、
温度が-20℃~-60℃である予備凍結過程、及び/又は
温度が-15℃~-35℃である昇華過程、及び/又は
温度が0℃~40℃である真空乾燥過程をさらに含む、
請求項1に記載の方法。 - 前記凍結乾燥過程は、
時間が5-15時間である予備凍結過程、及び/又は
時間が30-55時間である昇華過程、及び/又は
時間が4-10時間である真空乾燥過程をさらに含む、
請求項1に記載の方法。 - 請求項1に記載の方法で製造されたBPA凍結乾燥製剤。
- 請求項13に記載のBPA凍結乾燥製剤を含む、組成物。
- 請求項13に記載のBPA凍結乾燥製剤を含む、キット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910341883 | 2019-04-26 | ||
CN201910341883.5 | 2019-04-26 | ||
PCT/CN2020/086745 WO2020216334A1 (zh) | 2019-04-26 | 2020-04-24 | Bpa冻干制剂及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022519619A true JP2022519619A (ja) | 2022-03-24 |
JP7297077B2 JP7297077B2 (ja) | 2023-06-23 |
Family
ID=72941011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021545479A Active JP7297077B2 (ja) | 2019-04-26 | 2020-04-24 | Bpa凍結乾燥製剤及び製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20210338588A1 (ja) |
EP (1) | EP3960204A4 (ja) |
JP (1) | JP7297077B2 (ja) |
CN (2) | CN111920964B (ja) |
WO (1) | WO2020216334A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103100094A (zh) * | 2011-11-14 | 2013-05-15 | 中国原子能科学研究院 | 一种应用于l-bpa的冷冻干燥工艺 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5935944A (en) * | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
US6169076B1 (en) * | 1999-03-31 | 2001-01-02 | Glcosyn Pharmaceuticals, Inc. | P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols |
GB0222945D0 (en) * | 2002-10-03 | 2002-11-13 | Psimei Pharmaceuticals Plc | Therapeutic compositions |
MX2007012642A (es) * | 2005-04-11 | 2008-01-11 | Abbott Lab | Composiciones farmaceuticas que tienen perfiles mejorados de disolucion para farmacos poco solubles. |
JP5150084B2 (ja) * | 2006-10-17 | 2013-02-20 | 日本ケミカルリサーチ株式会社 | 高水溶性p−ボロノフェニルアラニン含有組成物 |
-
2020
- 2020-04-24 WO PCT/CN2020/086745 patent/WO2020216334A1/zh unknown
- 2020-04-24 CN CN202010333751.0A patent/CN111920964B/zh active Active
- 2020-04-24 CN CN202310405937.6A patent/CN116270504A/zh active Pending
- 2020-04-24 JP JP2021545479A patent/JP7297077B2/ja active Active
- 2020-04-24 EP EP20795662.4A patent/EP3960204A4/en active Pending
-
2021
- 2021-07-14 US US17/375,071 patent/US20210338588A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103100094A (zh) * | 2011-11-14 | 2013-05-15 | 中国原子能科学研究院 | 一种应用于l-bpa的冷冻干燥工艺 |
Non-Patent Citations (2)
Title |
---|
EUR. J. PHARMACEUT. SCI., vol. 48, JPN6022032151, 2013, pages 735 - 739, ISSN: 0004984053 * |
RADIOTHER. ONCOL., vol. 88, JPN6022032152, 2008, pages 183 - 191, ISSN: 0004984054 * |
Also Published As
Publication number | Publication date |
---|---|
EP3960204A1 (en) | 2022-03-02 |
EP3960204A4 (en) | 2022-07-06 |
US20210338588A1 (en) | 2021-11-04 |
CN111920964B (zh) | 2023-06-02 |
JP7297077B2 (ja) | 2023-06-23 |
CN111920964A (zh) | 2020-11-13 |
WO2020216334A1 (zh) | 2020-10-29 |
CN116270504A (zh) | 2023-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102086234B (zh) | 一种提高中分子量羟乙基淀粉质量的制备方法 | |
JP7007300B2 (ja) | ダパグリフロジンの新規な結晶形並びにその製造方法および用途 | |
JP6533235B2 (ja) | 生物医学的応用における使用のためのシクロデキストリンを組み入れたコラーゲンマトリクスを含む組成物 | |
CN101711746A (zh) | 一种注射用更昔洛韦冻干制剂及其制备方法 | |
JP2022519619A (ja) | Bpa凍結乾燥製剤及び製造方法 | |
CN102973524A (zh) | 一种埃索美拉唑钠冻干粉针剂及其制备方法 | |
RU2793921C1 (ru) | Способ получения лиофилизованного препарата bpa | |
CN102335114B (zh) | 一种稳定的布洛芬精氨酸注射剂及其制备方法 | |
CN107349181B (zh) | 含有瑞巴派特和聚维酮的眼科水悬浮液及其制备方法 | |
CN106619542B (zh) | 一种提高比伐卢定药物稳定性的方法 | |
CN114671924A (zh) | 一种美洲大蠊多肽提取物及其在口洁产品中的应用 | |
CN104473896B (zh) | 一种快速崩解的拉米夫定片及其制备工艺 | |
CN102335129B (zh) | 一种供注射用依达拉奉药物组合物及其制备方法 | |
CN103520192B (zh) | 一种注射用转化糖冻干粉针制剂制备方法 | |
CN111450048B (zh) | 一种退热贴用凝胶及其制备方法 | |
CN101590029B (zh) | 一种丙泊酚组合物 | |
CN110840849A (zh) | 一种用于5-氟尿嘧啶前药的粉针剂及其制备方法和应用 | |
CN103006584B (zh) | 一种注射用培美曲塞二钠的制备方法 | |
CN108272755B (zh) | 一种注射用盐酸吗替麦考酚酯冻干制剂及其制备方法 | |
CN103159709B (zh) | 穿琥宁的结晶及其制法 | |
CN102008734A (zh) | 一种α晶型伊马替尼的包合物及其制备方法 | |
CN101756895A (zh) | 一种多烯磷脂酰胆碱静脉制剂及其制备方法 | |
CN117224494A (zh) | 一种注射用氯诺昔康药物组合物及其制备方法 | |
CN107308152A (zh) | 一种双氯酚酸钠眼液 | |
CN114181129A (zh) | 一种制备不同粒度维格列汀的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210804 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230428 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230530 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230613 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7297077 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |